ArticlePloS one2025
Comparison of PSA Values from capillary dried blood spot analysis and venous serum samples.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) testing is a key tool in the early detection and monitoring of prostate cancer. While venous blood is the standard matrix for PSA measurement, capillary blood sampling represents a minimally invasive alternative that may facilitate broader access to testing. This prospective study investigated the agreement between capillary and venous measurements of total and free PSA in 224 male patients at ALTA Klinik Bielefeld, Germany. Blood samples were collected between April and June 2021 and analyzed using electrochemiluminescence immunoassays. The results showed strong correlations between capillary and venous samples for both total PSA (r = 0.99, p < 0.01) and free PSA (r = 0.98, p < 0.01). Mean differences were 0.35 ng/mL for total PSA and 0.27 ng/mL for free PSA. Bland-Altman analysis demonstrated good agreement between both methods, with most values falling within the 95% confidence limits. These findings suggest that capillary blood sampling may be a suitable alternative to venous blood for PSA testing, particularly within the clinically relevant range up to 10 ng/mL. Furthermore, the feasibility of determining both total and free PSA in capillary samples allows calculation of the fPSA/tPSA ratio, which may improve diagnostic specificity in early prostate cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.